Publication:
Human Plasma Metabolomics for Biomarker Discovery: Targeting the Molecular Subtypes in Breast Cancer.

dc.contributor.authorDíaz-Beltrán, Leticia
dc.contributor.authorGonzález-Olmedo, Carmen
dc.contributor.authorLuque-Caro, Natalia
dc.contributor.authorDíaz, Caridad
dc.contributor.authorMartín-Blázquez, Ariadna
dc.contributor.authorFernández-Navarro, Mónica
dc.contributor.authorOrtega-Granados, Ana Laura
dc.contributor.authorGálvez-Montosa, Fernando
dc.contributor.authorVicente, Francisca
dc.contributor.authorPérez Del Palacio, José
dc.contributor.authorSánchez-Rovira, Pedro
dc.date.accessioned2023-02-09T10:39:52Z
dc.date.available2023-02-09T10:39:52Z
dc.date.issued2021-01-05
dc.description.abstractThe aim of this study is to identify differential metabolomic signatures in plasma samples of distinct subtypes of breast cancer patients that could be used in clinical practice as diagnostic biomarkers for these molecular phenotypes and to provide a more individualized and accurate therapeutic procedure. Untargeted LC-HRMS metabolomics approach in positive and negative electrospray ionization mode was used to analyze plasma samples from LA, LB, HER2+ and TN breast cancer patients and healthy controls in order to determine specific metabolomic profiles through univariate and multivariate statistical data analysis. We tentatively identified altered metabolites displaying concentration variations among the four breast cancer molecular subtypes. We found a biomarker panel of 5 candidates in LA, 7 in LB, 5 in HER2 and 3 in TN that were able to discriminate each breast cancer subtype with a false discovery range corrected p-value 1.3. The model clinical value was evaluated with the AUROC, providing diagnostic capacities above 0.85. Our study identifies metabolic profiling differences in molecular phenotypes of breast cancer. This may represent a key step towards therapy improvement in personalized medicine and prioritization of tailored therapeutic intervention strategies.
dc.identifier.doi10.3390/cancers13010147
dc.identifier.issn2072-6694
dc.identifier.pmcPMC7795819
dc.identifier.pmid33466323
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7795819/pdf
dc.identifier.unpaywallURLhttps://www.mdpi.com/2072-6694/13/1/147/pdf?version=1609837200
dc.identifier.urihttp://hdl.handle.net/10668/16992
dc.issue.number1
dc.journal.titleCancers
dc.journal.titleabbreviationCancers (Basel)
dc.language.isoen
dc.organizationFundación MEDINA (Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucía)
dc.organizationHospital Universitario de Jaén
dc.organizationFundación MEDINA
dc.pubmedtypeJournal Article
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectbreast cancer
dc.subjecthuman plasma metabolomics
dc.subjectmetabolic profiling
dc.subjectmolecular subtypes
dc.subjectpersonalized medicine
dc.titleHuman Plasma Metabolomics for Biomarker Discovery: Targeting the Molecular Subtypes in Breast Cancer.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number13
dspace.entity.typePublication
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
PMC7795819.pdf
Size:
2.63 MB
Format:
Adobe Portable Document Format